Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1919 | Home sample collection of concerning mole with physician supervision Wiki | 0.58 |
| drug3837 | SSE educational intervention Wiki | 0.58 |
| drug221 | Active control:Healthy Living Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012056 | Cutaneous melanoma HPO | 1.00 |
| HP:0100526 | Neoplasm of the lung HPO | 0.14 |
Navigate: Correlations HPO
There are 3 clinical trials
This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.
Description: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.
Measure: Clinical data of lung cancer patients with COVID-19 diagnoses Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis
Measure: Diagnosis data Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received
Measure: Treatments received Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsDescription: Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors.
Measure: Prognostic factors Time: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 yearsThe purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in health promotion by having a recent screening mammogram are the focus of this research. Self-management of melanoma detection with SSE depends on ready access to dermatologists when a concerning mole is detected. In March 2020, the Illinois stay at home order (COVID-19) prohibited non-essential health care, including screening mammography and dermatology office-based care, and both are expected to remain limited until fall 2020. This submission explores a) the effectiveness of targeted melanoma detection (TMD) among women, who identify their risk of having a melanoma, learn to perform SSE, and perform SSE, and b) the effectiveness of adhesive patch-based home sample collection for genomic analysis to rule out melanoma in moles identified by women as concerning.
Description: Self-reported performance of SSE, a custom scale with the frequency and extent of SSE is completed in an online monthly survey
Measure: Change in SSE performance Time: 90 daysDescription: Self-reported identification of concerning mole identified by user assigning scores to the border,color and diameter of the mole. A validated scoring system is used to categorize the border, color and diameter as 1 if normal, 2 if not sure, and 3 if abnormal.The sum of the scores indicates if the mole is concerning (sum of 3= benign, stop checking the mole; sum of 4- 7 monitor the mole for change in the next month; sum of 8-9 = concerning mole make an appointment to see a physician.
Measure: Identification of concerning mole Time: 90 daysDescription: The quantity of cells obtained for genomic analysis will be assessed. The results of the genomic analysis will be validated with the pathological findings of the biopsied concerning mole. A Student t test will be performed for the null hypothesis of no difference between the genomic analysis and the pathological finding of melanoma.
Measure: Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma Time: 90 DaysDescription: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score= more anxiety
Measure: Change in skin self-examination anxiety Time: 90 daysDescription: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score = greater confidence.
Measure: Change in confidence performing mole checks Time: 90 daysDescription: Electronic medical record review
Measure: Number of physician visits for concerning moles Time: 5 monthsDescription: Electronic medical record review
Measure: Number of biopsies of concerning moles Time: 5 monthsThe primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data.
Description: Including exposure, risk factors, testing, isolation, seropositivity, hospitalization, or loss of family or friends.
Measure: Experiences during the COVID-19 pandemic Time: Survey completion Up to 2 monthsDescription: Will evaluate the extent to which resiliency factors such as social support and perceived benefits moderate the effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL.
Measure: Effects of COVID-19 experiences on COVID-19-specific psychological distress and HRQoL Time: Survey completion Up to 2 monthsDescription: Will explore the association between prior lifestyle data collected as part of PA15-0336 and COVID-19-specific psychological distress and HRQoL.
Measure: Prior lifestyle data Time: Survey completion Up to 2 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports